Resmetirom

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 421 publications

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

Journal: American family physician

Published: June 16, 2026

Pharmacokinetics, mass balance and metabolic profiling of resmetirom in healthy subjects and nonclinical metabolism and disposition.

Pharmacokinetics, mass balance and metabolic profiling of resmetirom in healthy subjects and nonclinical metabolism and disposition.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: June 10, 2026

Hepatic Steatosis: A Pandemic Disease Causing Serious Secondary Diseases.

Hepatic Steatosis: A Pandemic Disease Causing Serious Secondary Diseases.

Journal: Deutsches Arzteblatt international

Published: May 29, 2026

Byakangelicin alleviates metabolic dysfunction-associated steatohepatitis by selective inhibition of a non-canonical MTORC1 signaling pathway.

Byakangelicin alleviates metabolic dysfunction-associated steatohepatitis by selective inhibition of a non-canonical MTORC1 signaling pathway.

Journal: Autophagy

Published: May 19, 2026

Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.

Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.

Journal: Clinics in liver disease

Published: May 16, 2026

Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: Shared Mechanisms and Therapeutic Opportunities.

Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: Shared Mechanisms and Therapeutic Opportunities.

Journal: Cardiology in review

Published: May 13, 2026

Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps.

Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps.

Journal: Best practice & research. Clinical endocrinology & metabolism

Published: May 07, 2026

Current and future medical treatments for metabolic dysfunction-associated steatohepatitis

Current and future medical treatments for metabolic dysfunction-associated steatohepatitis

Journal: La Revue du praticien

Published: May 05, 2026

Fructose impairs brown adipogenesis by promoting thyroid hormone resistance in differentiated brown adipocytes.

Fructose impairs brown adipogenesis by promoting thyroid hormone resistance in differentiated brown adipocytes.

Journal: Biology open

Published: May 01, 2026

Lean Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): Pathophysiology, Diagnostic Challenges, Clinical Outcomes, and Management.

Lean Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): Pathophysiology, Diagnostic Challenges, Clinical Outcomes, and Management.

Journal: Diseases (Basel, Switzerland)

Published: April 20, 2026

When fatty liver fuels kidney cancer: the THRB connection.

When fatty liver fuels kidney cancer: the THRB connection.

Journal: Human cell

Published: April 08, 2026

Estimation of Rezdiffra (MGL-3196) by Validated RP-HPLC Approach in Bulk Material and Pharmaceutical Formulation.

Estimation of Rezdiffra (MGL-3196) by Validated RP-HPLC Approach in Bulk Material and Pharmaceutical Formulation.

Journal: Drug development and industrial pharmacy

Published: April 07, 2026

Showing 1-12 of 421

Last Updated: 06/30/2026